This is a single center, open label forced dose titration study designed to determine the
tolerability of curcumin in pediatric patients with inflammatory bowel disease (IBD). This
study will provide initial tolerability and safety data in pediatric patients with IBD.
Twenty patients with IBD in remission or with mild disease (score <34 on PUCAI or score <30
on the PCDAI) on sulfasalazine or mesalamine aged 8 to 18 years will be enrolled into this
study. Each patient will participate in the study for nine weeks. From this study an
appropriate dosage will be determined to proceed with a double blinded placebo controlled
study.